Haemophilus influenzae Type b Vaccine Failure in Children Is Associated with Inadequate Production of High-Quality Antibody
Background. Despite the excellent immunogenicity of Haemophilus influenzae type b (Hib) conjugate vaccines, breakthrough cases of Hib disease still affect a small proportion of vaccinated children in the United Kingdom. We performed a retrospective study to compare the avidity of antibody directed a...
Saved in:
| Published in | Clinical infectious diseases Vol. 46; no. 2; pp. 186 - 192 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Chicago, IL
The University of Chicago Press
15.01.2008
University of Chicago Press Oxford University Press |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1058-4838 1537-6591 1537-6591 |
| DOI | 10.1086/524668 |
Cover
| Abstract | Background. Despite the excellent immunogenicity of Haemophilus influenzae type b (Hib) conjugate vaccines, breakthrough cases of Hib disease still affect a small proportion of vaccinated children in the United Kingdom. We performed a retrospective study to compare the avidity of antibody directed against the Hib polysaccharide capsule (PRP) in children who experienced Hib vaccine failure in the United Kingdom among 3 historical cohorts and with age-matched healthy control subjects. Methods. Serum samples from vaccinated children with invasive Hib disease were collected beginning in 1992 as part of enhanced surveillance for Hib disease following vaccine introduction. A total of 251 children who experienced Hib vaccine failure were identified from 3 historical cohorts (1992–1995, 1996–1999, and 2000–2003). The anti-PRP antibody concentration and avidity from healthy age-matched control subjects was obtained for the 3 contemporary time points (1995, 1999, and 2002). Serum anti-PRP antibody concentration was measured in each of the samples using a standard Hib ELISA, and antibody avidity was determined using thiocyanate elution. Results. Within the first 60 days after disease onset, there was no change in the anti-PRP antibody avidity, and there was no statistically significant difference in the geometric mean Hib antibody avidity over the 3 study periods. However, the children who experienced Hib vaccine failure had significantly lower Hib antibody avidity than did healthy control subjects, despite a marked antibody response following infection. Conclusions. Children who experience Hib disease despite vaccination appear to have a defect in immunological priming, leading to a qualitative difference in Hib-specific memory B cells. Low anti-PRP antibody avidity decreases the functional activity of anti-PRP antibody in the sera of these children experiencing vaccine failure, leading to disease susceptibility. |
|---|---|
| AbstractList | Background. Despite the excellent immunogenicity of Haemophilus influenzae type b (Hib) conjugate vaccines, breakthrough cases of Hib disease still affect a small proportion of vaccinated children in the United Kingdom. We performed a retrospective study to compare the avidity of antibody directed against the Hib polysaccharide capsule (PRP) in children who experienced Hib vaccine failure in the United Kingdom among 3 historical cohorts and with age-matched healthy control subjects. Methods. Serum samples from vaccinated children with invasive Hib disease were collected beginning in 1992 as part of enhanced surveillance for Hib disease following vaccine introduction. A total of 251 children who experienced Hib vaccine failure were identified from 3 historical cohorts (1992–1995, 1996–1999, and 2000–2003). The anti-PRP antibody concentration and avidity from healthy age-matched control subjects was obtained for the 3 contemporary time points (1995, 1999, and 2002). Serum anti-PRP antibody concentration was measured in each of the samples using a standard Hib ELISA, and antibody avidity was determined using thiocyanate elution. Results. Within the first 60 days after disease onset, there was no change in the anti-PRP antibody avidity, and there was no statistically significant difference in the geometric mean Hib antibody avidity over the 3 study periods. However, the children who experienced Hib vaccine failure had significantly lower Hib antibody avidity than did healthy control subjects, despite a marked antibody response following infection. Conclusions. Children who experience Hib disease despite vaccination appear to have a defect in immunological priming, leading to a qualitative difference in Hib-specific memory B cells. Low anti-PRP antibody avidity decreases the functional activity of anti-PRP antibody in the sera of these children experiencing vaccine failure, leading to disease susceptibility. Despite the excellent immunogenicity of Haemophilus influenzae type b (Hib) conjugate vaccines, breakthrough cases of Hib disease still affect a small proportion of vaccinated children in the United Kingdom. We performed a retrospective study to compare the avidity of antibody directed against the Hib polysaccharide capsule (PRP) in children who experienced Hib vaccine failure in the United Kingdom among 3 historical cohorts and with age-matched healthy control subjects.BACKGROUNDDespite the excellent immunogenicity of Haemophilus influenzae type b (Hib) conjugate vaccines, breakthrough cases of Hib disease still affect a small proportion of vaccinated children in the United Kingdom. We performed a retrospective study to compare the avidity of antibody directed against the Hib polysaccharide capsule (PRP) in children who experienced Hib vaccine failure in the United Kingdom among 3 historical cohorts and with age-matched healthy control subjects.Serum samples from vaccinated children with invasive Hib disease were collected beginning in 1992 as part of enhanced surveillance for Hib disease following vaccine introduction. A total of 251 children who experienced Hib vaccine failure were identified from 3 historical cohorts (1992-1995, 1996-1999, and 2000-2003). The anti-PRP antibody concentration and avidity from healthy age-matched control subjects was obtained for the 3 contemporary time points (1995, 1999, and 2002). Serum anti-PRP antibody concentration was measured in each of the samples using a standard Hib ELISA, and antibody avidity was determined using thiocyanate elution.METHODSSerum samples from vaccinated children with invasive Hib disease were collected beginning in 1992 as part of enhanced surveillance for Hib disease following vaccine introduction. A total of 251 children who experienced Hib vaccine failure were identified from 3 historical cohorts (1992-1995, 1996-1999, and 2000-2003). The anti-PRP antibody concentration and avidity from healthy age-matched control subjects was obtained for the 3 contemporary time points (1995, 1999, and 2002). Serum anti-PRP antibody concentration was measured in each of the samples using a standard Hib ELISA, and antibody avidity was determined using thiocyanate elution.Within the first 60 days after disease onset, there was no change in the anti-PRP antibody avidity, and there was no statistically significant difference in the geometric mean Hib antibody avidity over the 3 study periods. However, the children who experienced Hib vaccine failure had significantly lower Hib antibody avidity than did healthy control subjects, despite a marked antibody response following infection.RESULTSWithin the first 60 days after disease onset, there was no change in the anti-PRP antibody avidity, and there was no statistically significant difference in the geometric mean Hib antibody avidity over the 3 study periods. However, the children who experienced Hib vaccine failure had significantly lower Hib antibody avidity than did healthy control subjects, despite a marked antibody response following infection.Children who experience Hib disease despite vaccination appear to have a defect in immunological priming, leading to a qualitative difference in Hib-specific memory B cells. Low anti-PRP antibody avidity decreases the functional activity of anti-PRP antibody in the sera of these children experiencing vaccine failure, leading to disease susceptibility.CONCLUSIONSChildren who experience Hib disease despite vaccination appear to have a defect in immunological priming, leading to a qualitative difference in Hib-specific memory B cells. Low anti-PRP antibody avidity decreases the functional activity of anti-PRP antibody in the sera of these children experiencing vaccine failure, leading to disease susceptibility. Background . Despite the excellent immunogenicity of Haemophilus influenzae type b (Hib) conjugate vaccines, breakthrough cases of Hib disease still affect a small proportion of vaccinated children in the United Kingdom. We performed a retrospective study to compare the avidity of antibody directed against the Hib polysaccharide capsule (PRP) in children who experienced Hib vaccine failure in the United Kingdom among 3 historical cohorts and with age-matched healthy control subjects. Methods . Serum samples from vaccinated children with invasive Hib disease were collected beginning in 1992 as part of enhanced surveillance for Hib disease following vaccine introduction. A total of 251 children who experienced Hib vaccine failure were identified from 3 historical cohorts (1992-1995, 1996-1999, and 2000-2003). The anti-PRP antibody concentration and avidity from healthy age-matched control subjects was obtained for the 3 contemporary time points (1995, 1999, and 2002). Serum anti-PRP antibody concentration was measured in each of the samples using a standard Hib ELISA, and antibody avidity was determined using thiocyanate elution. Results . Within the first 60 days after disease onset, there was no change in the anti-PRP antibody avidity, and there was no statistically significant difference in the geometric mean Hib antibody avidity over the 3 study periods. However, the children who experienced Hib vaccine failure had significantly lower Hib antibody avidity than did healthy control subjects, despite a marked antibody response following infection. Conclusions . Children who experience Hib disease despite vaccination appear to have a defect in immunological priming, leading to a qualitative difference in Hib-specific memory B cells. Low anti-PRP antibody avidity decreases the functional activity of anti-PRP antibody in the sera of these children experiencing vaccine failure, leading to disease susceptibility. Despite the excellent immunogenicity of Haemophilus influenzae type b (Hib) conjugate vaccines, breakthrough cases of Hib disease still affect a small proportion of vaccinated children in the United Kingdom. We performed a retrospective study to compare the avidity of antibody directed against the Hib polysaccharide capsule (PRP) in children who experienced Hib vaccine failure in the United Kingdom among 3 historical cohorts and with age-matched healthy control subjects. Serum samples from vaccinated children with invasive Hib disease were collected beginning in 1992 as part of enhanced surveillance for Hib disease following vaccine introduction. A total of 251 children who experienced Hib vaccine failure were identified from 3 historical cohorts (1992-1995, 1996-1999, and 2000-2003). The anti-PRP antibody concentration and avidity from healthy age-matched control subjects was obtained for the 3 contemporary time points (1995, 1999, and 2002). Serum anti-PRP antibody concentration was measured in each of the samples using a standard Hib ELISA, and antibody avidity was determined using thiocyanate elution. Within the first 60 days after disease onset, there was no change in the anti-PRP antibody avidity, and there was no statistically significant difference in the geometric mean Hib antibody avidity over the 3 study periods. However, the children who experienced Hib vaccine failure had significantly lower Hib antibody avidity than did healthy control subjects, despite a marked antibody response following infection. Children who experience Hib disease despite vaccination appear to have a defect in immunological priming, leading to a qualitative difference in Hib-specific memory B cells. Low anti-PRP antibody avidity decreases the functional activity of anti-PRP antibody in the sera of these children experiencing vaccine failure, leading to disease susceptibility. Despite the excellent immunogenicity of Haemophilus influenzae type b (Hib) conjugate vaccines, breakthrough cases of Hib disease still affect a small proportion of vaccinated children in the United Kingdom. We performed a retrospective study to compare the avidity of antibody directed against the Hib polysaccharide capsule (PRP) in children who experienced Hib vaccine failure in the United Kingdom among 3 historical cohorts and with age-matched healthy control subjects. Serum samples from vaccinated children with invasive Hib disease were collected beginning in 1992 as part of enhanced surveillance for Hib disease following vaccine introduction. A total of 251 children who experienced Hib vaccine failure were identified from 3 historical cohorts (1992-1995, 1996-1999, and 2000-2003). The anti-PRP antibody concentration and avidity from healthy age-matched control subjects was obtained for the 3 contemporary time points (1995, 1999, and 2002). Serum anti-PRP antibody concentration was measured in each of the samples using a standard Hib ELISA, and antibody avidity was determined using thiocyanate elution. Within the first 60 days after disease onset, there was no change in the anti-PRP antibody avidity, and there was no statistically significant difference in the geometric mean Hib antibody avidity over the 3 study periods. However, the children who experienced Hib vaccine failure had significantly lower Hib antibody avidity than did healthy control subjects, despite a marked antibody response following infection. Children who experience Hib disease despite vaccination appear to have a defect in immunological priming, leading to a qualitative difference in Hib-specific memory B cells. Low anti-PRP antibody avidity decreases the functional activity of anti-PRP antibody in the sera of these children experiencing vaccine failure, leading to disease susceptibility. |
| Author | Yu, Ly-Mee Booy, Robert Pollard, Andrew J. Slack, Mary P. E. Siegrist, Claire-Anne Heath, Paul T. Kelly, Dominic F. Lee, Yeh Chen Moxon, Richard E. |
| Author_xml | – sequence: 1 givenname: Yeh Chen surname: Lee fullname: Lee, Yeh Chen email: lyehchen@yahoo.com organization: University Department of Paediatrics, University of Oxford, Oxford – sequence: 2 givenname: Dominic F. surname: Kelly fullname: Kelly, Dominic F. organization: University Department of Paediatrics, University of Oxford, Oxford – sequence: 3 givenname: Ly-Mee surname: Yu fullname: Yu, Ly-Mee organization: Centre for Statistics in Medicine, Oxford – sequence: 4 givenname: Mary P. E. surname: Slack fullname: Slack, Mary P. E. organization: Haemophilus Reference Unit, Respiratory and Systemic Infection Laboratory, Health Protection Agency Centre for Infections, United Kingdom – sequence: 5 givenname: Robert surname: Booy fullname: Booy, Robert organization: National Centre for Immunisation Research and Surveillance, Sydney, Australia – sequence: 6 givenname: Paul T. surname: Heath fullname: Heath, Paul T. organization: Paediatrics Infectious Diseases, Division of Child Health, St. George's, University of London, London, United Kingdom – sequence: 7 givenname: Claire-Anne surname: Siegrist fullname: Siegrist, Claire-Anne organization: World Health Organization Collaborating Center for Neonatal Vaccinology, Departments of Pathology and Pediatrics, University of Geneva Medical School, Geneva, Switzerland – sequence: 8 givenname: Richard E. surname: Moxon fullname: Moxon, Richard E. organization: University Department of Paediatrics, University of Oxford, Oxford – sequence: 9 givenname: Andrew J. surname: Pollard fullname: Pollard, Andrew J. organization: University Department of Paediatrics, University of Oxford, Oxford |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19984686$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/18171249$$D View this record in MEDLINE/PubMed |
| BookMark | eNqF0VuL1DAUB_AiK-5F_QZKFNQXq7k0afo4DK4zsKDCesGXkKanTsZO0k1a1tEvb4YOsyAMPiXk_Ajn_M95duK8gyx7TPAbgqV4y2khhLyXnRHOylzwipykO-YyLySTp9l5jGuMCZGYP8hOiSQloUV1lv1ZaNj4fmW7MSLr2m4E91sDut72gGr0RRtjHaBLnUCAJNA82SaAQ8uIZjF6Y_UADbq1wwotnW7gZkwP6GPwzWgG6x3yLVrYH6v806g7O2zRzA229s32YXa_1V2ER_vzIvt8-e56vsivPrxfzmdXuUm9D7mGAoyBFsuKiaZuuGw5rnklCs4aXQnZUEJNARKEaE2tKaWCYyopNK1kmrGL7NX07-h6vb3VXaf6YDc6bBXBahefmuJL8uUk--BvRoiD2thooOu0Az9GVWJSUlKw_0JScUYZ4wk-_weu_RhcGldRUlW8THtI6OkejfUGmrvu9mtK4MUe6Gh01wbtjI13rqpkIaRI7vXkTPAxBmiVsYPeLWEIaYNHxz3wo7k8m6Af--PmyWTWcfDhoArMsJDlLol8qts4wK9DXYefSpSs5Grx7buqGMEFX0j1lf0Fgv_d1w |
| CODEN | CIDIEL |
| CitedBy_id | crossref_primary_10_1155_2008_628963 crossref_primary_10_1128_JCM_05476_11 crossref_primary_10_1128_CVI_00023_08 crossref_primary_10_1016_j_vaccine_2010_04_027 crossref_primary_10_1111_j_1348_0421_2009_00196_x crossref_primary_10_3390_vaccines11121846 crossref_primary_10_1016_j_ijid_2020_08_040 crossref_primary_10_1542_peds_2008_3645 crossref_primary_10_4161_hv_26109 crossref_primary_10_1080_21645515_2024_2342630 crossref_primary_10_5812_apid_82238 crossref_primary_10_1016_j_vaccine_2020_08_022 crossref_primary_10_1016_j_biologicals_2015_06_008 crossref_primary_10_1016_S1473_3099_19_30213_0 crossref_primary_10_1172_JCI91192 crossref_primary_10_1016_j_vaccine_2010_07_005 crossref_primary_10_1007_s11568_010_9135_0 crossref_primary_10_1016_j_vaccine_2011_12_099 crossref_primary_10_1016_S1473_3099_14_70027_1 crossref_primary_10_1586_14760584_7_9_1299 crossref_primary_10_1128_CVI_00481_09 crossref_primary_10_1111_j_1460_9592_2009_02999_x crossref_primary_10_1038_s41541_021_00337_0 crossref_primary_10_1097_INF_0b013e31824a9c37 crossref_primary_10_1128_CVI_00215_13 crossref_primary_10_1155_2022_4813199 crossref_primary_10_1016_j_eimc_2020_10_005 crossref_primary_10_1097_WCO_0b013e3283381751 crossref_primary_10_1016_j_vaccine_2008_12_060 crossref_primary_10_1016_j_medmal_2009_02_025 crossref_primary_10_1128_CVI_00039_13 crossref_primary_10_1093_cid_ciy842 crossref_primary_10_1016_j_eimce_2021_07_005 crossref_primary_10_1189_jlb_0312117 crossref_primary_10_1016_j_heliyon_2018_e00664 crossref_primary_10_1186_s13027_022_00451_1 crossref_primary_10_3390_vaccines12050516 crossref_primary_10_1038_s41541_024_00877_1 crossref_primary_10_1111_j_1348_0421_2010_00196_x crossref_primary_10_1134_S1068162021010106 crossref_primary_10_1186_s12936_019_2637_x crossref_primary_10_1111_j_1469_0691_2009_02945_x crossref_primary_10_1016_j_arcmed_2010_05_010 crossref_primary_10_1016_j_jiac_2021_07_023 crossref_primary_10_1016_j_micpath_2020_104644 crossref_primary_10_1111_j_1469_0691_2009_02841_x crossref_primary_10_1016_j_pathol_2024_02_013 crossref_primary_10_1016_j_vaccine_2017_05_018 crossref_primary_10_1128_CVI_00131_10 crossref_primary_10_1016_j_jiph_2017_07_008 crossref_primary_10_1016_j_earlhumdev_2010_08_010 crossref_primary_10_1038_s41467_019_11002_5 crossref_primary_10_1128_CVI_00248_16 crossref_primary_10_37349_ei_2022_00040 crossref_primary_10_4049_jimmunol_182_2_1211 crossref_primary_10_5812_pedinfect_82238 crossref_primary_10_1097_INF_0b013e31816fc339 crossref_primary_10_1111_j_1365_3024_2010_01259_x |
| Cites_doi | 10.1086/318132 10.1001/jama.283.21.2795 10.1136/adc.86.6.396 10.1002/1521-4141(200203)32:3<752::AID-IMMU752>3.0.CO;2-5 10.1093/infdis/167.5.1210 10.1086/314901 10.1093/infdis/165.4.753 10.1136/adc.75.2.159 10.1086/338259 10.1086/314989 10.1086/315511 10.1086/322024 10.1136/adc.77.6.488 10.3201/eid1206.051451 10.1111/j.1365-2567.2004.01971.x 10.1086/503775 10.1097/00007890-199403150-00009 10.1086/376997 10.1016/S0140-6736(03)13171-6 10.1097/00006454-199809001-00005 10.1097/00006454-200307000-00019 10.1001/jama.284.18.2334 10.1016/0022-1759(90)90264-V 10.1067/S0022-3476(03)00243-9 |
| ContentType | Journal Article |
| Copyright | Copyright 2007 Infectious Diseases Society of America 2008 by the Infectious Diseases Society of America 2008 2008 INIST-CNRS Copyright University of Chicago, acting through its Press Jan 15, 2008 |
| Copyright_xml | – notice: Copyright 2007 Infectious Diseases Society of America – notice: 2008 by the Infectious Diseases Society of America 2008 – notice: 2008 INIST-CNRS – notice: Copyright University of Chicago, acting through its Press Jan 15, 2008 |
| DBID | BSCLL AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7QL 7T2 7T7 7U7 7U9 8FD C1K FR3 H94 K9. M7N P64 7X8 ADTOC UNPAY |
| DOI | 10.1086/524668 |
| DatabaseName | Istex CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Bacteriology Abstracts (Microbiology B) Health and Safety Science Abstracts (Full archive) Industrial and Applied Microbiology Abstracts (Microbiology A) Toxicology Abstracts Virology and AIDS Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Algology Mycology and Protozoology Abstracts (Microbiology C) Biotechnology and BioEngineering Abstracts MEDLINE - Academic Unpaywall for CDI: Periodical Content Unpaywall |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Virology and AIDS Abstracts Technology Research Database Toxicology Abstracts Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Safety Science Abstracts Engineering Research Database Industrial and Applied Microbiology Abstracts (Microbiology A) Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Virology and AIDS Abstracts Bacteriology Abstracts (Microbiology B) |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1537-6591 |
| EndPage | 192 |
| ExternalDocumentID | 10.1086/524668 1408145591 18171249 19984686 10_1086_524668 40306875 ark_67375_HXZ_931045H8_W |
| Genre | Journal Article |
| GeographicLocations | United Kingdom--UK |
| GeographicLocations_xml | – name: United Kingdom--UK |
| GroupedDBID | --- ..I .2P .I3 .ZR 08P 0R~ 1TH 29B 2AX 2WC 36B 4.4 48X 53G 5GY 5RE 5VS 5WD 6J9 AABZA AACGO AACZT AAJKP AAJQQ AAMVS AANCE AAOGV AAPQZ AAPXW AAQQT AARHZ AAUAY AAUQX AAVAP ABBHK ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABLJU ABNGD ABNHQ ABOCM ABPLY ABPQP ABPTD ABQLI ABQNK ABTLG ABVGC ABWST ABXSQ ABXVV ACGFO ACGFS ACHIC ACPRK ACUFI ACUKT ACUTJ ACUTO ACYHN ADBBV ADGZP ADHKW ADHZD ADIPN ADNBA ADQBN ADQXQ ADRTK ADULT ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEUPB AEWNT AEXZC AFFNX AFFZL AFIYH AFOFC AFRAH AFXAL AGINJ AGORE AGQPQ AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AIAGR AJBYB AJEEA AJNCP ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN AQKUS AQVQM ASPBG ATGXG AVWKF AXUDD AZFZN BAWUL BAYMD BCRHZ BEYMZ BHONS BSCLL BTRTY BVRKM C1A C45 CDBKE CS3 CZ4 DAKXR DCCCD DIK DILTD DU5 D~K E3Z EBS EE~ EJD EMOBN ENERS F5P F9B FECEO FEDTE FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC H13 H5~ HAR HQ3 HTVGU HVGLF HW0 HZ~ IOX IPSME J21 JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JST JXSIZ KAQDR KBUDW KOP KSI KSN L7B MHKGH MJL ML0 N4W N9A NGC NOMLY NOYVH NU- NVLIB O0~ O9- OAUYM OAWHX OCZFY ODMLO ODZKP OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P P6G PAFKI PB- PEELM PQQKQ Q1. Q5Y QBD RD5 ROX ROZ RUSNO RW1 RXO SA0 SJN TCURE TEORI TJX TMA TR2 W8F X7H YAYTL YKOAZ YXANX ~91 ~S- AAYOK AASNB ADACV ADJQC ADRIX AFXEN DOOOF ESX JSODD M49 AAYXX CITATION .GJ 1KJ 3O- 70D AAPGJ AAPNW AAWDT ABKDP ABNKS ABSMQ ABZBJ ACFRR ACPQN ACVCV ACZBC ADEYI ADMTO ADOCK AEKPW AFFQV AFSHK AFYAG AGKEF AGKRT AGMDO AHGBF AI. AIJHB AJDVS APJGH AQDSO AVNTJ BZKNY EIHJH IQODW J5H MBLQV OBFPC O~Y VH1 Y6R ZGI CGR CUY CVF ECM EIF NPM 7QL 7T2 7T7 7U7 7U9 8FD C1K FR3 H94 K9. M7N P64 7X8 ADTOC UNPAY |
| ID | FETCH-LOGICAL-c483t-ae4eccef08936dbd58f50b596453da968d212c4e8e66fcba222650282edf83a33 |
| IEDL.DBID | UNPAY |
| ISSN | 1058-4838 1537-6591 |
| IngestDate | Wed Aug 20 00:17:04 EDT 2025 Thu Sep 25 08:50:17 EDT 2025 Sat Sep 27 16:00:41 EDT 2025 Fri Jul 25 04:07:41 EDT 2025 Thu Apr 03 06:55:50 EDT 2025 Mon Jul 21 09:11:36 EDT 2025 Wed Oct 01 02:08:58 EDT 2025 Thu Apr 24 23:08:28 EDT 2025 Wed Sep 11 04:50:51 EDT 2024 Thu Jun 19 15:26:46 EDT 2025 Sat Sep 20 11:01:48 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | Human Pasteurellaceae Prevention Immunoprophylaxis Antibody Pathogenesis Quality Bacteria Vaccine Child Failure Haemophilus influenzae |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c483t-ae4eccef08936dbd58f50b596453da968d212c4e8e66fcba222650282edf83a33 |
| Notes | istex:A230F702EBB79D0325187A3C41DA877E8EB5C798 ark:/67375/HXZ-931045H8-W ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://academic.oup.com/cid/article-pdf/46/2/186/1239884/46-2-186.pdf |
| PMID | 18171249 |
| PQID | 219957712 |
| PQPubID | 48300 |
| PageCount | 7 |
| ParticipantIDs | unpaywall_primary_10_1086_524668 proquest_miscellaneous_70172143 proquest_miscellaneous_19532335 proquest_journals_219957712 pubmed_primary_18171249 pascalfrancis_primary_19984686 crossref_citationtrail_10_1086_524668 crossref_primary_10_1086_524668 oup_primary_10_1086_524668 jstor_primary_40306875 istex_primary_ark_67375_HXZ_931045H8_W |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2008-01-15 |
| PublicationDateYYYYMMDD | 2008-01-15 |
| PublicationDate_xml | – month: 01 year: 2008 text: 2008-01-15 day: 15 |
| PublicationDecade | 2000 |
| PublicationPlace | Chicago, IL |
| PublicationPlace_xml | – name: Chicago, IL – name: United States – name: Oxford |
| PublicationTitle | Clinical infectious diseases |
| PublicationTitleAbbrev | Clinical Infectious Diseases |
| PublicationTitleAlternate | Clinical Infectious Diseases |
| PublicationYear | 2008 |
| Publisher | The University of Chicago Press University of Chicago Press Oxford University Press |
| Publisher_xml | – name: The University of Chicago Press – name: University of Chicago Press – name: Oxford University Press |
| References | (15_38579874) 1999; 180 (14_38726977) 1992; 165 (4_38409205) 2003; 188 Goldblatt (8_16461067) 1996; 75 Heath (3_17063310) 2002; 86 (20_38280194) 2004; 22 (12_38254303) 2000; 31 Heath (6_10539948) 2000; 284 Johnson (27_22154320) 2006; 12 Phipps (21_9274878) 1990; 135 (2_24051356) 1998; 17 McVernon (11_17741135) 2003; 22 Kelly (7_18320037) 2004; 113 (17_38580473) 1999; 180 Schallert (23_16936210) 2002; 32 Latal-Hajnal (1_17809248) 2003; 143 (25_38580036) 2000; 181 (26_38280195) 2001; 19 (24_38436275) 2006; 193 Heath (18_5915192) 1997; 77 McVernon (5_17620565) 2003; 361 (9_38727740) 1993; 167 (13_38268252) 2002; 34 (10_35193007) 1994; 57 (16_38419781) 2001; 184 MacLennan (19_10340875) 2000; 283 |
| References_xml | – volume: 31 start-page: 973 issn: 1058-4838 issue: 4 year: 2000 ident: 12_38254303 publication-title: Clinical Infectious Diseases doi: 10.1086/318132 – volume: 283 start-page: 2795 issn: 0098-7484 issue: 21 year: 2000 ident: 19_10340875 publication-title: JAMA doi: 10.1001/jama.283.21.2795 – volume: 86 start-page: 396 issn: 0003-9888 issue: 6 year: 2002 ident: 3_17063310 publication-title: Archives of Disease in Childhood doi: 10.1136/adc.86.6.396 – volume: 32 start-page: 752 issn: 0014-2980 issue: 3 year: 2002 ident: 23_16936210 publication-title: European journal of immunology doi: 10.1002/1521-4141(200203)32:3<752::AID-IMMU752>3.0.CO;2-5 – volume: 167 start-page: 1210 issn: 0022-1899 issue: 5 year: 1993 ident: 9_38727740 publication-title: Journal of Infectious Diseases doi: 10.1093/infdis/167.5.1210 – volume: 180 start-page: 538 issn: 0022-1899 issue: 2 year: 1999 ident: 15_38579874 publication-title: Journal of Infectious Diseases doi: 10.1086/314901 – volume: 165 start-page: 753 issn: 0022-1899 issue: 4 year: 1992 ident: 14_38726977 publication-title: Journal of Infectious Diseases doi: 10.1093/infdis/165.4.753 – volume: 75 start-page: 159 issn: 0003-9888 issue: 2 year: 1996 ident: 8_16461067 publication-title: Archives of Disease in Childhood doi: 10.1136/adc.75.2.159 – volume: 34 start-page: 191 issn: 1058-4838 issue: 2 year: 2002 ident: 13_38268252 publication-title: Clinical Infectious Diseases doi: 10.1086/338259 – volume: 180 start-page: 1390 issn: 0022-1899 issue: 4 year: 1999 ident: 17_38580473 publication-title: Journal of Infectious Diseases doi: 10.1086/314989 – volume: 181 start-page: 2117 issn: 0022-1899 issue: 6 year: 2000 ident: 25_38580036 publication-title: Journal of Infectious Diseases doi: 10.1086/315511 – volume: 184 start-page: 377 issn: 0022-1899 issue: 3 year: 2001 ident: 16_38419781 publication-title: Journal of Infectious Diseases doi: 10.1086/322024 – volume: 77 start-page: 488 issn: 0003-9888 issue: 6 year: 1997 ident: 18_5915192 publication-title: Archives of Disease in Childhood doi: 10.1136/adc.77.6.488 – volume: 12 start-page: 937 issn: 1080-6040 issue: 6 year: 2006 ident: 27_22154320 publication-title: Emerging infectious diseases doi: 10.3201/eid1206.051451 – volume: 113 start-page: 163 issn: 0019-2805 issue: 2 year: 2004 ident: 7_18320037 publication-title: Immunology doi: 10.1111/j.1365-2567.2004.01971.x – volume: 193 start-page: 1598 issn: 0022-1899 issue: 11 year: 2006 ident: 24_38436275 publication-title: Journal of Infectious Diseases doi: 10.1086/503775 – volume: 57 start-page: 677 issn: 1534-6080 year: 1994 ident: 10_35193007 doi: 10.1097/00007890-199403150-00009 – volume: 188 start-page: 481 issn: 0022-1899 issue: 4 year: 2003 ident: 4_38409205 publication-title: Journal of Infectious Diseases doi: 10.1086/376997 – volume: 361 start-page: 1521 issn: 0140-6736 issue: 9368 year: 2003 ident: 5_17620565 publication-title: Lancet doi: 10.1016/S0140-6736(03)13171-6 – volume: 22 start-page: 4262 issn: 1873-2518 year: 2004 ident: 20_38280194 – volume: 17 start-page: 117 issn: 0891-3668 year: 1998 ident: 2_24051356 publication-title: The Pediatric infectious disease journal doi: 10.1097/00006454-199809001-00005 – volume: 22 start-page: 659 issn: 0891-3668 issue: 7 year: 2003 ident: 11_17741135 publication-title: The Pediatric infectious disease journal doi: 10.1097/00006454-200307000-00019 – volume: 284 start-page: 2334 issn: 0098-7484 issue: 18 year: 2000 ident: 6_10539948 publication-title: JAMA doi: 10.1001/jama.284.18.2334 – volume: 135 start-page: 121 issn: 0022-1759 issue: 1-2 year: 1990 ident: 21_9274878 publication-title: Journal of immunological methods doi: 10.1016/0022-1759(90)90264-V – volume: 19 start-page: 2280 issn: 1873-2518 year: 2001 ident: 26_38280195 – volume: 143 start-page: 163 issn: 0022-3476 issue: 2 year: 2003 ident: 1_17809248 publication-title: The Journal of pediatrics doi: 10.1067/S0022-3476(03)00243-9 |
| SSID | ssj0011805 |
| Score | 2.1958568 |
| Snippet | Background. Despite the excellent immunogenicity of Haemophilus influenzae type b (Hib) conjugate vaccines, breakthrough cases of Hib disease still affect a... Background . Despite the excellent immunogenicity of Haemophilus influenzae type b (Hib) conjugate vaccines, breakthrough cases of Hib disease still affect a... Despite the excellent immunogenicity of Haemophilus influenzae type b (Hib) conjugate vaccines, breakthrough cases of Hib disease still affect a small... |
| SourceID | unpaywall proquest pubmed pascalfrancis crossref oup jstor istex |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 186 |
| SubjectTerms | Antibodies Antibodies, Bacterial - blood Antibodies, Bacterial - immunology Antibody affinity Antibody Affinity - immunology Articles and Commentaries Bacterial Capsules Biological and medical sciences Child, Preschool Children Children & youth Cohort Studies Comparative analysis Conjugate vaccines Disease Susceptibility Female General aspects Haemophilus Infections - blood Haemophilus Infections - immunology Haemophilus Infections - microbiology Haemophilus Infections - prevention & control Haemophilus influenzae Haemophilus influenzae type b Haemophilus influenzae type b - immunology Haemophilus Vaccines - immunology Haemophilus Vaccines - therapeutic use Human infectious diseases. Experimental studies and models Humans Immune response Infant Infections Infectious diseases Influenza Male Medical sciences Pediatrics Polysaccharides Polysaccharides, Bacterial - immunology Polysaccharides, Bacterial - therapeutic use Retrospective Studies Studies Treatment Failure Vaccination Vaccines Vaccines, Conjugate - immunology Vaccines, Conjugate - therapeutic use |
| Title | Haemophilus influenzae Type b Vaccine Failure in Children Is Associated with Inadequate Production of High-Quality Antibody |
| URI | https://api.istex.fr/ark:/67375/HXZ-931045H8-W/fulltext.pdf https://www.jstor.org/stable/40306875 https://www.ncbi.nlm.nih.gov/pubmed/18171249 https://www.proquest.com/docview/219957712 https://www.proquest.com/docview/19532335 https://www.proquest.com/docview/70172143 https://academic.oup.com/cid/article-pdf/46/2/186/1239884/46-2-186.pdf |
| UnpaywallVersion | publishedVersion |
| Volume | 46 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1537-6591 dateEnd: 20241002 omitProxy: true ssIdentifier: ssj0011805 issn: 1058-4838 databaseCode: DIK dateStart: 19960101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwEB4trcRDiNeykF0oPgA3t01iO-6xWlG1oF3tgULhEjmOA9WWpGwbQZc_zzivLY-KA1d72jqer_E3nhfAc60DZEGBoonSMWXISGnk9_vU-FxHChXOmU1wPjkV4yl7PeOzPRjVuTCqigrvNikNqJNqE-kyTnpM9LyeK0XPtZXrJMMB6lEc6OLsNWgL62hqQXt6ejb8ULg6eXFjJsvCqQEVfOBuNRniHhO2zurWqdS2G_y9DlCsM99uL9UKty0p-138jZDeght5ulSbb2qx2DqkRnfhU_14ZWzKeTdfR119-Vvlx_9__ntwp-KxZFh-5j7smfQBXD-pPPX78GOszJds-Xm-yFdkXnZCuVSGWLuXROSd0laOjNTcxsWjBDmu0srJZEVq0JiY2ItiMklxvV9zHCBnZYlahBPJEmLDVGhZB2RDhul6HmXx5iFMR6_eHo9p1eiBatTMmirDEEkm6SN5EnEUc5nwfsQHgnE_VgMhYzxgNTPSCJEghJDTILFEY9HEifSV7x9AK81S8xhIJBPtJXGitbRcxYt86we2eeJIfeNg4MCLWtGhrqqg22Yci7DwxksRloBw4Fkjtyzrfvwh8bLASTOtLs5tlFzAw_HsYzhA3sz4WIbvHTgogNQIMmunoZ3owCFqeefXd34B3JUYGshMSOHAUY3AsHrvrELPZtwHgevh-ptZfGFYL5BKTZavQus39Xyf75YIinsB5jvwqAT21W9LN7Ddyh0gDdJ3rP_w3yJHcLOMvnGpy59Aa32Rm6dI8dZRB42byZtO9S_-CTXPSG8 |
| linkProvider | Unpaywall |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LbxMxEB6VRIIixLuwLRQfgJuT7K7tdY5RRZQiteqBQOCy8nptiJpuQpMVpPx5xvtqeEQcuNqTxOv5sv7G8wJ4qXWELChS1CqdUoaMlCZhr0dNyHWiUOGcuQTnk1MxGrO3Ez7ZgWGdC6OqqPBOk9KAOqk2kS5S22WiG3R9Kbq-q1wnGQ7QgOJAB2dvQFs4R1ML2uPTs8HHwtXJixszWRZOjajgfX-jyRAPmHB1VjdOpbbb4O91gGKd-XZnoZa4bbbsd_E3QnobbuXZQq2_qdls45Aa3oPP9eOVsSnnnXyVdPTVb5Uf___578PdiseSQfmZB7Bjsodw86Ty1D-CHyNlLuaLL9NZviTTshPKlTLE2b0kIe-VdnJkqKYuLh4lyFGVVk6Ol6QGjUmJuygmxxmu92uOA-SsLFGLcCJzS1yYCi3rgKzJIFtNk3m6fgzj4Zt3RyNaNXqgGjWzosowRJKxPSRPIk1SLi3vJbwvGA9T1RcyxQNWMyONEBYhhJwGiSUaiya1MlRhuAetbJ6Zp0ASaXVgU6u1dFwlSELnB3Z54kh906jvwata0bGuqqC7ZhyzuPDGSxGXgPDgRSO3KOt-_CHxusBJM60uz12UXMTj0eRT3EfezPhIxh882CuA1AgyZ6ehnejBPmp569cf_gK4azE0kJmQwoODGoFx9d5ZxoHLuI8iP8D1N7P4wnBeIJWZeb6Mnd80CEO-XSIq7gVY6MGTEtjXvy39yHUr94A0SN-y_v1_ixzAbhl941OfP4PW6jI3z5HirZLD6v_7E4jcR3Y |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Haemophilus+influenzae+Type+b+Vaccine+Failure+in+Children+Is+Associated+with+Inadequate+Production+of+High-Quality+Antibody&rft.jtitle=Clinical+infectious+diseases&rft.au=Lee%2C+Yeh+Chen&rft.au=Kelly%2C+Dominic+F.&rft.au=Yu%2C+Ly-Mee&rft.au=Slack%2C+Mary+P.+E.&rft.date=2008-01-15&rft.pub=University+of+Chicago+Press&rft.issn=1058-4838&rft.volume=46&rft.issue=2&rft.spage=186&rft.epage=192&rft_id=info:doi/10.1086%2F524668&rft.externalDocID=40306875 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1058-4838&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1058-4838&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1058-4838&client=summon |